Clinical Trials Browser

Phase 1/2 × Recruiting × XELOX × Clear all

NCT07334431 2026-01-12

Fruquintinib Combined With Trastuzumab and XELOX as First-line Treatment in Patients With HER2-positive Advanced Gastric Cancer

Phase 1/2 Recruiting

Gastrointestinal

Stomach Neoplasms

NCT06650332 2024-10-21

Cadonilimab Combination Regimen as First-line Treatment for HER2-expressing GC/GEJ Patients

Phase 1/2 Recruiting

Gastrointestinal

Metastatic HER2 Positive Gastroesophageal Junction Cancer